Similar articles

• Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.

  Weiler S, Zoller H, Graziadei I, Vogel W, Bellmann-Weiler R, Joannidis M, Bellmann R. Weiler S, et al. Antimicrob Agents Chemother. 2007 Sep;51(9):3459-60. doi: 10.1128/AAC.00791-07. Epub 2007 Jul 2. Antimicrob Agents Chemother. 2007. PMID: 17606679 Free PMC article. No abstract available.
• Clinical pharmacokinetics of voriconazole.

  Levêque D, Nivoix Y, Jehl F, Herbrecht R. Levêque D, et al. Int J Antimicrob Agents. 2006 Apr;27(4):274-84. doi: 10.1016/j.ijantimicag.2006.01.003. Epub 2006 Mar 24. Int J Antimicrob Agents. 2006. PMID: 16563707 Review.
• Pharmacokinetics of voriconazole during continuous venovenous hemofiltration.

  Spriet I, Wauters J, Willems L. Spriet I, et al. Ther Drug Monit. 2011 Jun;33(3):372; author reply 372. doi: 10.1097/FTD.0b013e31821f38bf. Ther Drug Monit. 2011. PMID: 21566509 No abstract available.
• Random plasma concentrations of voriconazole decline over time.

  Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Mulanovich V, et al. J Infect. 2007 Nov;55(5):e129-30. doi: 10.1016/j.jinf.2007.07.019. Epub 2007 Sep 5. J Infect. 2007. PMID: 17804077
• Pharmacological aspects of the new triazole voriconazole.

  Ullmann AJ. Ullmann AJ. Ann Hematol. 2002;81 Suppl 2:S50-1. Ann Hematol. 2002. PMID: 12611077 Review. No abstract available.